Search Results

The SPQTM Antibody Reagent Set for Lp(a) is designed for the quantitative determination of human lipoprotein(a) in human serum by immunoprecipitin analysis using a turbidimetric clinical analyzer. The measurement of Lp(a) is indicated for use in conjunction with clinical evaluation, patient risk assessment and other lipoprotein tests to evaluate disorders of lipid metabolism and to assess coronary heart heart disease (CHD) in male Caucasian populations.

The SPQ™ Test System for Lp(a) provides the quantitative determination of human lipoprotein(a) by automated immunoprecipitin analysis. Standards, controls, and samples are pipetted undiluted into sample cups. Microvolumes of these samples and a polymeric enhancer are pipetted into individual cuvettes. Following an initial incubation and measurement of sample blank, undiluted antiserum is added to the cuvettes. The sample and antiserum are mixed in the reaction cuvettes. Reaction temperature is controlled at 37°C. Insoluble antibody complexes form immediately, producing turbidity in the mixture and increasing the amount of light scattered by the solution. The amount of antigen-antibody complex formed, and thus the amount of light scatter, is proportional to the amount of lipoprotein(a) in the initial sample. The solution absorbance is measured after a 10 minute incubation period.

A calibration curve is generated by analyzing a series of calibrators with known concentrations of lipoprotein(a) and using the instrument's data reduction capability or manually plotting the change in absorbance versus lipoprotein(a) concentration. Concentrations of lipoprotein(a) within the controls and samples are interpolated from the calibration curve.

The test is designed for use on instruments capable of immunoprecipitin analysis, as the Cobas FARA II. The instruments measure the amount of light scattering in the reaction cuvettes due to the formation of insoluble antigen-antibody complexes. The systems are capable of storing a calibration curve. This assay is not designed for manual use.

Here's an analysis of the provided text, focusing on acceptance criteria and study details:

Device & Intended Use:
The device under consideration is the SPQ™ Test System Antibody Reagent Set for Lp(a). It's an immunoprecipitin assay for the quantitative determination of human lipoprotein(a) in human serum using a turbidimetric clinical analyzer. Its intended use is to evaluate lipid metabolism disorders and assess coronary heart disease (CHD) in male Caucasian populations, in conjunction with clinical evaluation, patient risk assessment, and other lipoprotein tests.

1. Table of Acceptance Criteria and Reported Device Performance

The document does not explicitly state acceptance criteria in a quantitative format (e.g., "correlation coefficient must be > X"). However, based on the reported performance, we can infer what was considered acceptable for market clearance. The "performance data" section effectively serves as a demonstration of meeting implied acceptance criteria by showing good correlation, discrimination between populations, and reproducibility within reasonable limits for an immunoassay.

2. Sample Size Used for the Test Set and Data Provenance

• Clinical Correlation Study:
  • Sample Size: Not explicitly stated as "sample size." However, the study involved a "normal population with known cardiac risk factors" and a "population with known atherosclerotic heart disease." The number of individuals in these populations is not provided.
  • Data Provenance: Not explicitly stated (e.g., country of origin). The study is retrospective in the sense that populations are identified by "known" conditions/risk factors.
• Correlation Studies (vs. NWLRL and Macra):
  • Sample Size: Not explicitly stated.
  • Data Provenance: Not explicitly stated.
• Recovery Study:
  • Sample Size: Not explicitly stated how many "Lp(a) polymorphs" were tested or how many replicate measurements were made.
  • Data Provenance: Not explicitly stated.
• Reproducibility Study:
  • Sample Size: 6 samples (spanning the assay range) + 2 control samples. Each sample/control was tested in duplicate, once a day for 7 days over a 2-week period. This results in 14 data points per sample/control per site (7 days * 2 replicates). The table shows N=42, which likely refers to the total number of individual measurements for each sample across all sites (3 sites * 7 days * 2 replicates = 42).
  • Data Provenance: Not explicitly stated. It's a prospective study designed specifically for reproducibility assessment.

3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications of Those Experts

• No information provided regarding the number or qualifications of experts used to establish ground truth for any of the studies (clinical correlation, correlation to reference/predicate, recovery, or reproducibility).
• For the clinical correlation, the "known cardiac risk factors" and "known atherosclerotic heart disease" imply a clinical diagnosis was made by healthcare professionals, but no details are given about how these diagnoses were standardized or adjudicated for the purpose of the study.

4. Adjudication Method for the Test Set

• No information provided on any explicit adjudication method (e.g., 2+1, 3+1).
• For the clinical correlation, the basis for categorizing individuals into "normal" and "diseased" populations relies on "known" conditions, which presumes prior clinical assessment, but the study itself does not describe an active adjudication process for its test set.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done

• No, an MRMC comparative effectiveness study was not done.
• This device is an in vitro diagnostic (IVD) assay, not an imaging or diagnostic support AI device that would typically involve human readers. Its performance is measured directly through its quantitative output and correlation to reference methods and clinical outcomes, not by comparing human reader performance with and without AI assistance.

6. If a Standalone (i.e., Algorithm Only Without Human-in-the-Loop Performance) Was Done

• Yes, the provided performance data represents standalone performance.
• The "SPQ Test System" is an automated immunoprecipitin analysis system. The data presented (clinical correlation, correlation to other assays, recovery, reproducibility) characterizes the performance of the device itself (the reagent set used on a turbidimetric analyzer like the Cobas FARA II) without requiring a human-in-the-loop to interpret its primary output (quantitative Lp(a) levels). A human then uses these quantitative results in conjunction with other clinical information, but the assay's performance is standalone.

7. The Type of Ground Truth Used

• Clinical Correlation: Clinical diagnosis/categorization of individuals as "normal with cardiac risk factors" or "with known atherosclerotic heart disease." This relies on outcomes data and prior clinical evaluation.
• Correlation to Reference Methods: The "Northwest Lipid Research Laboratory reference method" and the "Strategic Diagnostics Macra assay" served as the ground truth proxies for comparison.
• Recovery Study: The "known concentrations of Lp(a) polymorphs" (implied, as the study evaluates quantitative recovery) serve as the intended ground truth.
• Reproducibility Study: "Known" Lp(a) levels in the control samples and the average concentrations of test samples after multiple runs serve as the ground truth for assessing variability.

8. The Sample Size for the Training Set

• Not applicable / No information provided.
• This device is a reagent set for an immunoassay, not a machine learning algorithm that requires a separate "training set" in the conventional sense. The development of such assays typically involves optimization and validation steps, but these are not referred to as "training" in the context of AI/ML.

9. How the Ground Truth for the Training Set Was Established

• Not applicable. As stated above, this is not an AI/ML device that uses a "training set."

Ask a specific question about this device